Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Total raised: $5.34M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.11.2023 | Seed | $5.34M | - |
Mentions in press and media 5
| Date | Title | Description |
| 15.11.2023 | Scotland-based Glox Therapeutics raises GBP 4.3 million in Seed funding | Glasgow, Scotland-based company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, Glox Therapeutics, raised GBP 4.3M in seed funding. The company announced the investment on November 13,... |
| 14.11.2023 | Glox Therapeutics Raises £4.3M in Seed Funding | Glox Therapeutics, a Glasgow, Scotland, UK-based developer of precision antibiotic therapies based on naturally occurring bacteriocins, raised £4.3M in seed funding. The round was led by Boehringer Ingelheim Venture Fund and Scottish Enterp... |
| 14.11.2023 | Scotland’s Glox Therapeutics raises €4.9M to combat antimicrobial resistance | Read this article in: Glasgow-based Glox Therapeutics, a company that aims to advance its precision antibiotic therapies, focusing on naturally occurring bacteriocins, has secured £4.3M (approximately €4.93M) in a seed round of funding. The... |
| 14.11.2023 | Glox Therapeutics secures £4.3M seed funding to develop precision antimicrobials targeting drug-resistant bacteria | Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria Investment to accelerate development of a novel class of targeted high-potency bacteriocins against specific antimicrobial-re... |
| - | Glox Therapeutics | “Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.” |